In Parting Shot At Pharma, Trump CMS Weakens Part D Patient Protections

By John Wilkerson / January 19, 2021 at 8:12 PM
CMS is using a demonstration to weaken two pillars of patient protections in Part D: protected drug classes and the requirement that insurers cover at least two drugs in each class. Two consecutive administrations failed to follow through with proposals to weaken the six drug classes, and sources said the decision to test the policy is a parting shot from an administration that is angry at the drug industry for blocking one of President Donald Trump’s biggest campaign promises. Antiretrovirals,...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.